Today, the screeners at HealthTechMovers.com picked up 4 HealthTech Stocks up over 82% past 10 days and have been added to our watchlist. These are very volatile stocks so please do your own research before you make any investments. While we list the ratings of various 3rd party services, we're not recommending these stocks and we're not paid by the featured tickers, we simply report the big movers. If the editor has a position, it will be noted below the charts.
WallStreetMovers.com is also looking into these tickers BMRN, PEPG, BLCO, COO, SAGE.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
Rain Therapeutics, RAIN
Summary: Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies which target oncogenic drivers. The company's lead product candidate includes RAIN-32. Rain Therapeutics Inc. is based in NEWARK, Calif.
Recent RAIN Stock Price (approx 10:00am EST.): $5.81
Previous Close for RAIN Stock: $4.94
Percentage Price Change Past 10 Days for RAIN stock: +150%
TipRanks.com reports that Rain Therapeutics stock currently has 4 analysts offering 12-month price targets and the consensus is a Strong Buy rating for RAIN stock with an average price target is $16.33.
Click here to get the full story on RAIN stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Clovis Oncology, Inc. is a biopharmaceutical companyfocused on acquiring, developing and commercializing innovative anti-cancer agents.'Clovis has only one marketed drug in its portfolio a poly ADP-ribose polymerase inhibitor, namely Rubraca that is approved for the treatment of certain patients with ovarian and prostate cancer.'Currently, Rubraca is approved in the United States for two indications specific to ovarian cancer in the second and third or later-line setting. The drug is also approved in the United States under accelerated approval as monotherapy for treating BRCA-mutant metastatic castrate-resistant prostate cancer.'A broad development program on Rubraca is currently underway across a variety of solid tumors. Clovis is looking to expand Rubraca's label into additional cancer types like breast and gastroesophageal cancers, among others. Meanwhile, Clovis holds global development and commercialization rights to Rubraca.
Recent CLVS Stock Price (approx 10:00am EST.): $2.28
Previous Close for CLVS Stock: $1.8
Percentage Price Change Past 10 Days for CLVS stock: +101%
TipRanks.com reports that Clovis Oncology stock currently has n/a analysts offering 12-month price targets and the consensus is a Hold rating for CLVS stock with an average price target is n/a.
Click here to get the full story on CLVS stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: Anebulo Pharmaceuticals Inc. is a clinical-stage biotechnology company. It involved in developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The company's product candidate includes ANEB-001. Anebulo Pharmaceuticals Inc. is based in Texas, United States.
Recent ANEB Stock Price (approx 10:00am EST.): $5.50
Previous Close for ANEB Stock: $5.2
Percentage Price Change Past 10 Days for ANEB stock: +86%
TipRanks.com reports that Anebulo Pharmaceuticals stock currently has n/a analysts offering 12-month price targets and the consensus is a Moderate Buy rating for ANEB stock with an average price target is n/a.
Click here to get the full story on ANEB stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Summary: HTG Molecular Diagnostics, Inc. is engaged in developing and marketing a technology platform which consists of instrumentation, consumables and software analytics for sample profiling applications including tumor profiling, molecular diagnostic testing and biomarker development. Its products include HTG Edge System, HTG Edge Assays and HTG Assay Direct. HTG Molecular Diagnostics, Inc. is headquartered in Tucson, Arizona.
Recent HTGM Stock Price (approx 10:00am EST.): $1.08
Previous Close for HTGM Stock: $1.03
Percentage Price Change Past 10 Days for HTGM stock: +82%
TipRanks.com reports that HTG Molecular Diagnostics stock currently has 1 analysts offering 12-month price targets and the consensus is a Moderate Buy rating for HTGM stock with an average price target is $3.00.
Click here to get the full story on HTGM stock >>
Pricing & Percentages as of approximately 10:00am EST.
-----------------------------------------------------------------------------------------
Just a reminder, one resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
The other great tool for charting is TradingView.com, so you might want to check that out too.
The information in this article was pulled from third part services. The prices listed above are not real-time and will be delayed at least 15 minutes.
WallStreetMovers.com keeps investors informed of the top moving stocks within each sector including Health & Biotech, Technology, Energy, Metals & Mining, Financial, Consumer, Communication Services and more. We provide investors with timely information regarding top moving stocks that is sourced from our proprietary stocks screens, partner stock analysts and breaking news that identify and monitor stocks that are on the move. Join thousands of investors who already signed up for our free subscription to WallStreetMovers.com.
